PACAP1-38, pituitary adenylate cyclase activating polypeptide; i.v., intravitreal; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; NBL, neuroblast layer; GCL, ganglion cell layer; 3 Abstract PACAP1-38, a ubiquitous and multifunctional regulator has been in the focus of neurotoxicity research due to its impressive neuroprotective potential. Although the literature extensively demonstrated its repressive effect on the apoptotic machinery in neurodegenerative models, there is a striking absence of analysis on its role in normal development. We performed quantitative analyses on caspase activity in developing retina upon 100, 50, 25 or 1 pmol intravitreal PACAP1-38 injection from postnatal day 1 (P1) through P7 in Wistar rats. Retinas were harvested at 6, 12, 18, 24 or 48 hours post-injection.
Introduction
PACAP1-38 has been proved to be an ubiquitous and pleiotropic regulator involved in various physiological processes in mammals (i.e. secretion of hormones, saliva secretion, glucose and lipid metabolism, blood pressure regulation, circadian rhythm, food intake) (Vaudry et al. 2009; Dickson and Finlayson, 2009 ). In addition to mature tissues, and its receptors are expressed in prenatal as well as early postnatal stages, indicating a disparate array of developmental functions in a wide range of vertebral nervous systems from fish to human (Olianas et al, 1997; Erhardt et al, 2001; Ciarlo et al, 2007; Alexandre et al, 2011) . The list of functions includes neurite outgrowth, neurogenesis, migration, differentiation, and last but not least, neuroprotection (Falluel-Morel et al, 2005 , Meyer 2006 Ogata et al, 2015) . Evidently, the versatile effects correlate with differential expression of PACAP receptors and their isoforms. To date, PACAP1-38 can signal through three major receptors (PAC1, VPAC1 and VPAC2). Moreover, insertion or deletion of cassettes into the third intracellular loop and/or the N-terminal region of PAC1-R results in 16 isoforms in mammals characterized with various affinities and signaling pathways (Blechman and Levkowitz 2013) . More precisely, intracellular loop variants (Null, Hip, Hop1, Hop2, Hiphop1, Hiphop2) have been identified based on the presence of one or two 28 amino acid cassettes (Dickson and Finlayson 2009) . In rat retina, PACAP1-38 can signal via VPAC1, VPAC2 and 4 PAC1 receptor isoforms (Null, Hip, Hop1 and Hiphop1), each of them displaying a unique time-curve of expression (Lakk et al, 2012; Denes et al, 2013) .
No doubt, the most noteworthy feature of PACAP1-38 is its significant anti-apoptotic effect. Apoptosis, the highly regulated and evolutionarily conserved program of cellular suicide, plays a key role in elimination of unwanted cells in order to establish proper cell number during histogenesis. In addition to normal development, dysregulated and excess apoptosis contributes to neurodegenerative diseases, thus investigation of apoptotic process has been in the focus of neurotoxicity research (Endres et al, 1998; Daemen et al, 1999; Barber 2003) . The apoptotic machinery is composed of both pro-apoptotic and anti-apoptotic factors, at ratios that determine cellular survival or death. Members of cysteinyl aspartate specific proteinase (caspase) family create a multiple, cross-linked cascade system that plays the central role in both initiation (i.e. caspase-2, -8, -9, -10, -11 and -12) and execution (i.e. caspase-3, -6 and -7) of apoptosis (Nicholson 1999; Matteson and Chan, 2003; Deniaud et al, 2008) . There are three ways to induce apoptosis. While external cues activate death receptors, internal cues trigger the apoptotic cascade through mitochondria or endoplasmic reticulum (Ashkenazi and Dixit, 1999; Breckenridge et al, 2003; Jeong and Seol, 2008) . Either way, executioner caspase-3, the hub of all apoptotic pathways, undergoes cleavage and proceeds the demolition phase of cell death along with caspase-7 and 6 (Slee et al, 2001 ).
The number of reports proving the repressive effect of PACAP1-38 on the apoptotic machinery in various neurodegenerative models is impressive. It is important to point out, however, that PACAP1-38 has been investigated exclusively when apoptosis had been induced either by an exogenous agent, such as ethanol, nitroprusside, tumor necrosis factoralpha, ketamine or glutamate (Tamás et al, 2004; Sanchez et al, 2009; Botia et al, 2011; Bian et al, 2017; Mansouri et al, 2017) or by pathological conditions (e.g. diabetes, ischemia, osteoarthritis) (Dohi et al, 2002; Gabriel 2013; Giunta et al, 2015) . A number of studies demonstrated the neuroprotective potential of PACAP1-38 including the retina (Shioda et al, 2016) . However, the role of PACAP1-38 in normal apoptosis accompanying retinal development is far from being elaborately investigated. Developmental apoptosis sweeps through the retina in two waves coinciding first with neurogenesis in early prenatal phase then with synaptogenesis in the postnatal phase (Bahr, 2000) . To be strictly defined, ganglion cells undergo dramatic loss due to programmed cell death during the first postnatal week of retinal development in rats as well as mice (Cunningham et al., 1981; Perry et al., 1983; Young, 1984) . The multi-layered ganglion cell layer (GCL) of newborn rats is dramatically extenuating by the age of postnatal day 8 (P8) and develops into a single-layered structure by P14 (Vrolyk et al., 2018) . Therefore, the aim of the present study is to provide data on the role of this peptide in retinal apoptosis during the first postnatal week. We report here for the first time that PACAP1-38 has a stage-dependent and opposing effect on developmental apoptosis. Consistent with its neuroprotective reputation, PACAP1-38 evokes anti-apoptotic effect but only in P3 retinas using high dosage. In the same, earlier or later developmental stages, PACAP1-38 also appeared to facilitate apoptosis in dosage as low as 1pmol.
Experimental Procedures

Animals, treatments, tissue preparation
Postnatal day 1 (P1)-, three (P3)-, five (P5) and seven (P7)-days old albino Wistar rats, equal number of both males and females were used for this study. Animal handling, housing and experimental procedures were reviewed and approved by the ethical committee of University of Pécs (PTE/43902/2016). All efforts were made to minimize pain. Animals were anaesthetized by inhalation using Forane prior to treatment or sacrifice. PACAP1-38 (Bio Basic Canada Inc., Markham, Canada) was injected intravitreally (i.v.) into one eye of the animals meanwhile the paired eye was injected with the same volume of 0.9% saline. To prevent rapid degradation of PACAP1-38, N-terminally acetylated PACAP1-38 was used . Eyes were removed and retinas were dissected in cold, phosphatebuffered saline. Upon dissection, tissues were frozen on dry ice and stored at -80 C° until processed.
Caspase3/7 assays
To monitor the changes in Casp-3/7 enzymatic activity in response to 2.5 μl 0.2 μg/μl (100 pmol) i.v. PACAP1-38 injection, P1, P3, P5 and P7 pups were treated. Retinas were collected at 6, 12, 18, 24 and 48 hours following PACAP1-38 treatment. At P3, two further experimental groups were created. In both groups, pups were treated with either 50 or 25 or 1 pmol PACAP1-38 but one group was sacrificed in 18 hours post-injection meanwhile the other group was terminated in 24 hours post-injection. Tissues were processed according to the instructions of Apo-ONE Homogeneous Caspase-3/7 Assay (Promega, Madison, WI) except that tissue lysis was performed in hypotonic lysis buffer (20 mM TRIS-HCl, 10 mM NaCl, 3 mM MgCl 2 , 2 µg/ml aprotinin, 0.5 µg/ml leupeptin). Homogenized samples were centrifuged at 4 °C and supernatants were used for the assay. Caspase substrate, Z-DEVD-R110 was added to samples and incubated for 30 up to 90 minutes. Casp-3/7 activity was reflected in the intensity of fluorescent signal released by Z-DEVD-R110 upon cleavage.
Protein concentration of the samples was determined with BCA TM Protein Assay Kit (Pierce, Rockford, IL) in order to normalize fluorescence signal to protein concentration and express it as fluorescence/mg protein. Using control samples as references, ratios were calculated and relative change in caspase activity in each experimental group was expressed as mean percentages ± SD. For statistical analysis, first, normality was tested using Shapiro-Wilk test.
Then, to identify groups whose means were significantly different from the mean of the reference groups we used independent sample t-test. A value of p≤0.05 was considered statistically significant.
Western blot
To detect changes in the amount of initiator caspases, retinas were treated at P3 with 2.5 μl 0.2 μg/μl (100 pmol) PACAP1-38 but harvested in 24 hours following PACAP1-38 injection. For protein extraction, tissues were homogenized in 300 µl RIPA buffer (10 mM phosphate buffer pH 7.2, 1% NP-40, 1% Na-deoxycholate, 0.1% SDS, 0.15 M NaCl, 2 mM EDTA, 2 µg/ml aprotinin, 0.5 µg/ml leupeptin, 2 mM sodium vanadate, 20 mM sodium fluoride, 0.5 mM DTT, 10 mM PMSF) with micropestles on ice for 5 minutes. Thereafter, samples were centrifuged at 4 °C and the supernatants saved. Protein concentration was 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) test
TUNEL test was performed on P4 retinas (n=3) dissected in 24 hours post-injection.
Eyecups were fixed in 2% buffered paraformaldehyde (PFA) for 2 hours at room temperature followed by washing in phosphate buffered saline (PBS area or along 100 µm length, respectively, in three PACAP1-38 treated retina.
Results
PACAP1-38 regulates caspase 3/7 activity on a developmental stage-dependent manner
We analyzed the effect of i.v. injected PACAP1-38 on retinal apoptosis on a precise developmental time course covering the first postnatal week from P1 through P7. In our previous study, we proved that 100 pmol PACAP1-38 could affect gene expression as early as 3 hours post-injection with a sustained down or upregulation up to 24 hours (Lakk et al. 2017 ). Therefore, we investigated Casp 3/7 activity upon PACAP1-38 treatment at 6, 12, 18, 24, 48 hour time points.
When PACAP1-38 was administered to P1 retina, no changes in Casp-3/7 activity could be detected at 6 (n=5) or 12 hours (n=5) (Fig. 1A) . As PACAP1-38 was reported to repress apoptosis (Dejda et al, 2008) , a surprising elevation (125.8±18, n=4, p=0.048) was observed at 18 hours post-injection in response to PACAP1-38 treatment. The effect was only transient, however, as at 24 (n=5) or 48 hours (n=5) post-injection the same caspase activity was measured in both treated and control retinas.
Injection of PACAP1-38 in a later developmental stage, at P3, resulted in a biphasic effect (Fig. 1B) . No changes in Casp-3/7 activity were observed until 18 hours post-injection, when a significant drop was detected (49.5±21.3, n=4, p=0.006). Thereafter, Casp-3/7 activity showed a significant and transient increase (120±6.7, n=3, p=0.014) at 24 hours following treatment and it was again normalized at 48 hours (n=5).
When PACAP1-38 was injected into eyes of 5 days old rats (Fig. 1C) , anti-apoptotic effect could not be observed. Nevertheless, a significant elevation of Casp-3/7 activity 9 (131.18±15.75, n=5, p=0.002) was measured at 18 hours post-injection. In the two remaining time points (i.e 24h, 48h, n=4, n=4, respectively), no changes were induced by PACAP1-38.
Finally, PACAP1-38 appeared to have no effect on apoptosis at P7 (Fig 1D) .
Measuring Casp3/7 activity in 6-12-18-24-48 hours (n=4 in all groups) upon PACAP1-38 injection, no changes could be detected.
Gradually decreasing concentration does not affect pro-apoptotic but diminishes antiapoptotic action of PACAP1-38
Two prominent time points were chosen in P3 animals (P3-18h and P3-24h) in order to further analyze the effects of the peptide on apoptosis. In Fig 2A, it is clearly demonstrated that PACAP1-38 could block apoptosis only in a dosage as high as 100 pmol at 18 hours (n=3). Decreasing amount of PACAP1-38 (i.e. 50-25-1 pmol, n=4, n=4, n=4, respectively)
could not exert inhibition on the apoptotic cascade. Interestingly, reduction of PACAP1-38 concentration did not affect its pro-apoptotic action. Fig 2B shows that 50 , 25, or even 1 pmol (n=3, n=4, n=3, respectively) PACAP1-38 could increase significantly the Casp-3/7 activity in P3 retinas at 24 hours.
PACAP1-38 turns on the intrinsic route of apoptosis by activating both Casp-9 and Casp-12
Results obtained from the caspase assays clearly indicated that PACAP1-38 has a proapoptotic potential in 24 hours upon treatment in P3 retinas. Subsequently, the expression of initiator Casp-9 and Casp-12 were measured. As a consequence of PACAP1-38 injection, both Casp-9 (Fig. 3A) and Casp-12 ( Fig. 3B) showed a remarkable increase in 24 hours.
PACAP1-38 induces a systematic apoptosis in the developing retina
Once pro-apoptotic action of PACAP1-38 was proven, we investigated the localization of dying cells in the retina. Based on the results of the caspase assay, cells undergoing apoptosis upon PACAP1-38 treatment were mapped in P4 retinas at 24 hours post-injection.
In P4 control retinas, TUNEL positive cells could hardly be observed (Fig. 4 , panel A) thus for better orientation DAPI was used as a counter staining (Fig 4. panel A' ). PACAP1-38 injection had a dramatic effect on the number of apoptotic cells (Fig 4. panel B) . injection. In control tissues, there was a negligible number of TUNEL positive cells in this developmental period. Taking into account that apoptosis is a kinetic process, also, the quick clearance of the dying cells (Galli-Resta and Ensini, 1996) , it is crucial to note that the above numbers of apoptotic cells reflect only a momentary physiology.
Discussion
It is unquestionable that PACAP1-38 has earned a remarkable neuroprotective reputation based on its anti-apoptotic action in various degenerative models (Dejda et al., 2008) . It is also well-established that PACAP1-38 exerts its powerful anti-apoptotic effect through activation of multiple signaling pathways involving ERK or P13-kinase/Akt or blocking of potassium channels (Bhave and Hoffman, 2004; Mei et al. 2004; Li et al; . It is important to point out, however, that its effects on apoptotic pathways have been examined under pathological conditions when cell death was induced by various stresses (e.g. growth factor withdrawal, ethanol, oxidative stress, etc) (Vaudry et al., 2002; Scharf et al., 2008; Masmoudi-Kouki et al., 2011) . Very few papers have intended to provide evidence how PACAP1-38 contributes to regulation of developmental apoptosis. Vaudry et al. (2000) reported that PACAP1-38 inhibited caspase activity and increased viability of developing cerebellar granule cells in vitro. Furthermore, apoptosis of chick neuroblasts was increased by blocking PAC1 receptors, however, exogenously administered PACAP1-38 appeared to be ineffective (Erhardt and Sherwood, 2004) .
Likewise, conspicuous number of reports has been providing data on the retinoprotective functions of PACAP1-38 (Shioda et al., 2016) . Nevertheless, the present study is the first, which aimed to investigate in vivo the role of PACAP1-38 in normal apoptosis in the postnatal mammalian retina. Here, we examined on a precise developmental time scale how and when PACAP1-38 affects developmental apoptosis in the rat retina.
Surprisingly, we detected anti-apoptotic action only when PACAP1-38 was injected into P3
eyes. In P1, P5 or P7 retinas, PACAP1-38 did not exert anti-apoptotic action. In reflection of that vast amount of data proving anti-apoptotic role of the peptide, it seems that PACAP1-38
does not interfere with normal apoptotic processes but suppresses their activation induced at pathological levels. A similar phenomenon was reported by Hamelink et al (2002) , who demonstrated that although PACAP is evidently a sympathoadrenal co-transmitter, basal adrenaline secretion in PACAP KO mice did not appear to be altered. Nevertheless, animals were vulnerable to prolonged metabolic stresses since adrenaline secretion could not be stimulated in absence of PACAP when it was needed.
Furthermore, anti-apoptotic effect was exerted only by 100 pmol PACAP1-38. Lower amount (i.e. 50, 25, 1 pmol) was truly ineffective, although PACAP1-38 was reported to inhibit ethanol or anisomycin-induced apoptosis at concentration as low as 1 or 0.1 pM, respectively (Silveira et al., 2002; Vaudry et al., 2002) . In the present experiments, only a relatively high dosage could evoke anti-apoptotic effect. Numerous pharmacological studies provided evidence that PACAP1-38 has potency to signal via VPAC1 and VPAC2 receptors and exert neuroprotective effects (Dejda et al., 2006) . Considering that PACAP1-38 has a much lower potency to stimulate either cAMP or Ca 2+ response through VPAC1 and VPAC2
receptors (Dickson et al., 2006) , it is reasonable to assume that the high dosage of PACAP1-38 could signal via VPAC1 causing a subsequent inhibition of caspase activity. Both the expression of VPAC1 in the postnatal rat retina and its well established inhibitory effect on apoptosis give the rationale to this assumption (Zupan et al., 2000; Calafat et al., 2009; Lakk et al., 2012; Yu et al., 2017) . Interestingly, PACAP1-38 exerted anti-apoptotic action only at P3. Stage-dependent action of any regulators can be explained by either differential expression of their receptors or by the sensitivity of the target cell population. The exclusive anti-apoptotic effect cannot be explained by differential expression of PAC1 or VPAC1
receptors, since they do not display any changes from P0 through P5 (Lakk et al., 2012) . It has been indicated by several reports that sensitivity of retinal cells to cell death depends on intracellular pathways activated in distinct stages of differentiation (Chiarini et al, 2003; Campos et al, 2006) . Therefore, the matter, why retinal cells are responsive to the antiapoptotic effect of PACAP1-38 only at P3 definitely prompts further studies.
Not only that anti-apoptotic effect was restricted to a single developmental stage, but the suppression of Casp-3 and 7 was rather a transient action followed by the activation of the executioner caspases. What counts more here is the evidence that PACAP1-38 appears to have a remarkable stage-dependent pro-apoptotic action throughout the first postnatal week.
As TUNEL test demonstrated, PACAP1-38 triggers apoptosis in the GCL and the inner part of the NBL where ganglion cells and putative newborn amacrine cells develop, respectively. Vrolyk et al (2018) investigating the postnatal development of ocular structures in rats, described developmental apoptosis in the GCL between P1 and P8 whereas did not find notable apoptotic activity in the NBL during maturation. Consequently, PACAP1-38 might very well contribute to the normal cell death of ganglion cell population, meanwhile it might act as a selective regulator in NBL eliminating non-preferred cells that are sensitive for such external cues.
Another key thing to discuss is the concentration-dependent manner of PACAP1-38 activities. That is to say, once injected, only 100 pmol PACAP could evoke inhibition of Casp-3 and 7 at P3, lower amount were ineffective, whereas significant apoptotic action could be induced even by 1 pmol PACAP1-38. One can speculate that after longer times, the peptide is subject to dilution or/and the action of tissue peptidases and could not signal through low affinity receptors such as VPAC1. High affinity receptors, namely PAC1, 13 however could still initiate signaling pathway that can result in activation of apoptotic enzymes. Since apoptotic effects were rather delayed in 18 or 24 hours post-injection, the other possible explanation of the apoptotic effect is that PACAP1-38 acted indirectly through the induction of another secreted regulator. Our recent work (Lakk et al., 2017 ) also supports mechanism of the hysteretic way of PACAP1-38. We showed that the development of the newborn retina is orchestrated by interaction between all PACAP receptors and critically important proteins such as members of the fibroblast growth factor and bone morphogenic protein families (Lakk et al., 2017) . The findings suggest that PACAP1-38 can play multiple roles in a variety of developmental processes as a secretagouge, and furthermore, this may also include apoptotic action.
The only developmental stage when PACAP1-38 seemed to be ineffective was the end of the first postnatal week (i.e. P7). A reasonable explanation may relate to the significant expression changes PAC1 receptor isoforms undergo during this period. By dramatically down regulating the Hip isoform, the retina switches to Hop1 receptors. More specifically, we
showed that Hip expression declined at P6 and remained down regulated through P10 (Denes et al., 2014) . Supporting this scenario of the changing outcome of PACAP1-38 regulation is the observation that PACAP1-38 can act as both a mitogenic and anti-mitogenic factor depending on the differential expression of PAC1 receptor isoforms (Lu et al., 1998; Yan et al., 2013) .
All things considered, it seems very likely that multiple PACAP1-38 receptors with different affinities or with different sets of downstream mediator(s) are involved in the opposing effects. The unique, biphasic biology of PACAP1-38 regulation is puzzling and warrants further studies to identify the receptors and signaling pathways mediating the proapoptotic effect.
In summary, this is the first report on the role of PACAP1-38 in developmental apoptosis and we provide experimental evidence of the pro-apoptotic function of PACAP1-38 in the mammalian retina. Our results elucidate a new feature of this multifaceted peptide and suggest that PACAP1-38 contributes to the establishment of the proper retinal architecture by controlling ganglion and amacrine cell numbers in postnatal development. 
